Assembly Biosciences, Inc (ASMB)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 73
- Market Cap
- $516M
About Assembly Biosciences, Inc
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
SentiSense also tracks daily options readings for Assembly Biosciences, Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Assembly Biosciences, Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.